Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

May 29, 2013

Impacting Clinical and Preclinical Decisions: Computational Analysis of Complex Genomics Data Sets

Speaker for this Event:
  • Sergey Stepaniants, Ph.D., Head of Computational Biology, Genomics Laboratory, Covance  Learn More
  • The paradigm of ‘one drug, one target’ is evolving to understanding complex biological systems that can help predict the adverse effects of a drug or the therapeutic effects of a drug.

    This talk will discuss the use of computational biology tools to ensure high-quality genomics when used as part of the QC process. Additionally, computational tools can be applied to complex data sets to identify key clinical targets even in complex data sets.

    Examples included will highlight the use of these computational tools to identify key clinical markers to guide decision making in clinical trials.


    Drug development scientists, researchers and decision makers with a focus on genomics, next generation sequencing, genomics data sets, computational biology and application of genomic data in clinical trials.


    Sergey Stepaniants, Ph.D., Head of Computational Biology, Genomics Laboratory, Covance

    Sergey Stepaniants, Ph.D., is Head of Computational Biology, Covance Genomics Laboratory. Sergey received his M.S. from the Moscow Institute for Physics and Technology and his Ph.D. from the University of Rhode Island in Theoretical Physics and Applied Mathematics. He began his Computational Biology career as a postdoctoral fellow at the University of Illinois and Beckman Institute for Advanced Studies. Sergey has more than 15 years experience in genomics and genetics data analysis, focusing on biomarker/target discovery in pre-clinical and clinical experiments. Sergey has also been published in numerous peer-reviewed journals.


    Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies, with annual revenues greater than $2 billion and more than 11,000 employees in more than 60 countries. Covance has the people, processes, client service, and global resource capabilities to respond to biotechnology and pharmaceutical clients' toughest drug development challenges.

    Covance Discovery and Translational Services more effectively and efficiently bridges research gaps by providing integrated solutions throughout preclinical and clinical phases of development. Only Covance drives innovative pipeline development—by integrating Lead Optimization safety and efficacy services with expert capabilities in Biomarkers, Genomics, Antibody Products & Immunology Services.

    For information about the recorded archive for this event contact Xtalks at (416) 977-6555 ext 371, or email register@xtalks.com

    Copyright © 2016-2017 Honeycomb Worldwide Inc.